Efficacy and Effectiveness of PegInterferon and Ribavirin in Korean Patients With Chronic Hepatitis C

• Status: Completed
• Trial end date: 2012-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the efficacy and effectiveness of peginterferon alfa-2a and ribavirin therapy in Korean chronic hepatitis C patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asan Medical Center
• Collaborators: Gangnam Severance Hospital; Korea University Guro Hospital; Samsung Medical Center; Seoul St. Mary's Hospital; Severance Hospital
• Treatments: Interferon-alpha; Peginterferon alfa-2a; Ribavirin

Criteria

Inclusion Criteria: all of below

• adults aged 18-70 years

• serum anti-HCV antibody (+)

• HCV RNA detectable by PCR

• compensated liver disease (Child-Pugh class A)

Exclusion Criteria: any of below

• HCV genotype other than 1, 2, or 3

• acute hepatitis C

• decompensated cirrhosis or hepatocellular carcinoma

• other liver disease such as hepatitis A or B, or autoimmune hepatitis

• HIV Ab(+)

• severe depression or other psychiatric disease

• previous organ transplantation

• absolute neutrophil count (ANC) < 1,000 cells/mm3 or platelet count < 75,000 cells/mm3, or hemoglobin (Hb) < 13 g/dL for men, <12 g/dL for women